EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)

Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis

Ryota Tamura iD, Yoshiharu Yamanobe iD, Masato Fujioka iD, Yukina Morimoto, Mariko Fukumura, Masato Nakaya, Yumiko Oishi iD, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara iD, Tetsuro Hikichi, Shinobu Noji iD und 7 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.02376 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Ryota Tamura und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Cancer Vaccines, Neurilemmoma, Vascular Endothelial Growth Factor Receptor-1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184). MATERIALS AND METHODS VEGFR1 and VEGFR2 peptides were injected subcutaneously into infra-axillary and inguinal regions, once a week for 4 weeks and then once a month for 4 months. The primary end point was safety. Secondary end points included tolerability, hearing response, imaging response, and immunologic response. RESULTS Sixteen patients with NF2 with progressive schwannomas completed treatment and were assessed. No severe vaccine-related adverse events occurred. Among the 13 patients with assessable hearing, word recognition score improved in five patients at 6 months and two at 12 months. Progression of average hearing level of pure tone was 0.168 dB/mo during the year of treatment period, whereas long-term progression was 0.364 dB/mo. Among all 16 patients, a partial response was observed in more than one schwannoma in four (including one in which Bev had not been effective), minor response in 5, and stable disease in 4. Both VEGFR1-specific and VEGFR2-specific cytotoxic T lymphocytes (CTLs) were induced in 11 patients. Two years after vaccination, a radiologic response was achieved in nine of 20 assessable schwannomas. CONCLUSION This study demonstrated the safety and preliminary efficacy of VEGFR peptide vaccination in patients with NF2. Memory-induced CTLs after VEGFR vaccination may persistently suppress tumor progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Cancer VaccinesNeurilemmomaVascular Endothelial Growth Factor Receptor-1HumansMaleFemaleAdultMiddle AgedSkin NeoplasmsNeurofibromatosis 2Young AdultAgedNeurofibromatoses

Substanzen

Vascular Endothelial Growth Factor Receptor-2Cancer VaccinesVascular Endothelial Growth Factor Receptor-1KDR protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan.
  • Department of Molecular Genetics, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
  • OncoTherapy Science, Inc, Kanagawa, Japan.

ORCID-Profile: Ryota Tamura, Yoshiharu Yamanobe, Masato Fujioka, Yumiko Oishi, Hirokazu Fujiwara, Shinobu Noji, Naoki Oishi, Yutaka Kawakami

Zitieren

APA

Tamura, R., Yamanobe, Y., Fujioka, M., Morimoto, Y., Fukumura, M., Nakaya, M., Oishi, Y., Sato, M., Ueda, R., Fujiwara, H., Hikichi, T., Noji, S., Oishi, N., Ozawa, H., Ogawa, K., Kawakami, Y., Ohira, T., Yoshida, K., & Toda, M. (2024). Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02376

Vancouver

Tamura R, Yamanobe Y, Fujioka M, Morimoto Y, Fukumura M, Nakaya M, et al. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02376

BibTeX
@article{Tamura2024,
  author = {Tamura, Ryota and Yamanobe, Yoshiharu and Fujioka, Masato and Morimoto, Yukina and Fukumura, Mariko and Nakaya, Masato and Oishi, Yumiko and Sato, Mizuto and Ueda, Ryo and Fujiwara, Hirokazu and Hikichi, Tetsuro and Noji, Shinobu and Oishi, Naoki and Ozawa, Hiroyuki and Ogawa, Kaoru and Kawakami, Yutaka and Ohira, Takayuki and Yoshida, Kazunari and Toda, Masahiro},
  title = {Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02376}
}
Kostenlos starten →